Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study

In Switzerland, rituximab (RTX) is licenced for the treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitis (AAV) but is frequently used off-label to treat other auto-immune diseases (AID), espec...

Source: Arthritis Research and Therapy - June 1, 2023 Category: Rheumatology Authors: Alexandre Dumusc, Fahad Alromaih, Matthieu Perreau, Thomas H ügle, Pascal Zufferey and Diana Dan Tags: Research Source Type: research